Tumor recurrence and metastasis develop as a result of tumors' acquisition of anti-apoptotic mechanisms and therefore, it is necessary to develop novel effective therapeutics against metastatic cancers. In this study, we showed the differential TRAIL responsiveness of human prostate adenocarcinoma PC3 and human colon carcinoma KM12 cells and their… (More)
Figure 10 Effect of DMNB on TRAIL-induced cytotoxicity and apoptosis. PC3 (A) and KM12 (B) cells were treated with the indicated doses of TRAIL in the presence or absence of DMNB (1, 5, or 10 μM), and cell survival was determined after 96 h of incubation using the MTT assay (left). PC3 and KM12 cells were treated with the indicated doses of TRAIL in the presence or absence of 5 μM DMNB for 6 or 8 h, respectively. Thereafter, the percentage of apoptotic cells was determined using Annexin V staining and flow cytometry (right). Each point is the average of triplicate determinants. *p < 0.05, **p < 0.01, ***p < 0.001.